Parkinsonism and Anesthesia

Slides:



Advertisements
Similar presentations
Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
Drugs for Parkinson’s Disease & Psychotherapeutics NSG 106 Pharmacotherapeutics.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 5 th Lecture.
Presented by Abdulaziz .M. Al-Saad
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
Number of neurotransmitters  Neurotransmitters are chemicals capable of transmitting a signal from the pre-synaptic to the post synaptic neurone  Over.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Parkinson's Disease ILOs
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Neurotransmitters in the Brain. What are the different neurotransmitters in the brain? Currently, over 60 different molecules meet the criteria for being.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Pharmacology Nursing C ONTINUE CNS D RUGS Lecture 7.
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinsonism.
MOVEMENT DISORDERS.
DRUGS FOR PARKINSONISM
Drugs of Anti-Parkinson’s disease
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Central Nervous System
Anti-parkinsonism Drugs
Cholinergic Antagonist
Cholinergic Antagonist
Anti-parkinsonism Drugs
Antiparkinsonian drugs Presented by K.Lakshmi Department of pharmacology Assistant professor SSPC.
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Neurodegenerative diseases
Management in Primary Care
Copyright © 2011 by Elsevier Inc. All rights reserved.
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Parkinsonism and Anesthesia R2 Guo Shu-lin 2002.12.5 2018/11/22 Parkinsonism and Anesthesia

Two Challenge to Anesthetist Manage elderly patients lesser pulmonary reserve poorer cardiovascular function Acute disturbances of motor control during or after anesthesia rigid chest wall motion poor cooperation to region anesthesia 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Pathophysiology Loss of pigmented cells in the substantia nigra. A deficiency of dopamine leads to a dopamine/ acetylcholine imbalance Sub-clinical phase: decreased pigmented cells can compensate the effect of loss neurons 2018/11/22 Parkinsonism and Anesthesia

Clinical Presentation Hypokinesia: difficulty in initiating and slowness in executing movement Rigidity: throughout the whole range of movement of a joint Tremor: most pronounced at rest and a frequency of 4-8 Hz 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Current Treatment Dopamine precursor: Levodopa (L-dopa) Peripheral decarboxylase inhibitor: Carbidopa Anti-cholinergic drug: benztropine Mono-amine oxidase inhibitor-B (MAOI-B): Selegiline Dopamine agonist: Bromocriptine 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia 2018/11/22 Parkinsonism and Anesthesia

Anesthetic Considerations Pre-operative assessments Anti-parkinsonism drugs using principles Anesthetic decisions Peri-operative management Post-operative management 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Drug using principles Recommend that L-dopa uses just 20 min po before operation begins Recheck the last time of taking medicine MAOI drug should be hold to prevent hypertension crisis, but MAOI-B can use before operation Continuation of therapy perioperatively to avoid laryngospasm, aspiration pneumonia, hallucinations and violent tremors 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Anesthetic Decision Discussion with surgeon about the length of time and the strength of anesthesia L-dopa half-life is short about 1-3 hrs Only L-dopa (no carbidopa) iv form is available 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Anesthetic Decision Regional anesthesia Subjective feeling of Parkinsonism attack Drug given by po Difficultly apply on the patients with violent tremor or severe rigidty 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Anesthetic Decision General anesthesia Provide a good surgical condition Inhalation agent may affect dopamine activity Muscle relaxants mask the myopotential Difficult maintain anti-parkinsonism drugs Severe nausea and vomiting in these patients after general anesthesia 2018/11/22 Parkinsonism and Anesthesia

Peri-operative management Opioid-induced muscle rigidity Patients with Parkinsonism with three fold more incidence than normal geriatric population Opioid can inhibit the release of dopamine in CNS Infusion of fentanyl 300μg/min or total dose of 50 μg/kg resulted in difficulty with ventilation 2018/11/22 Parkinsonism and Anesthesia

Peri-operative management Inhalational agents Increase extracellular dopamine concentration in brain Block the dopamine transport by synaptosomes Decreased dopaminergic transmission, inhibit the dopamine reuptake, and then accumulation of extracellular dopamine 2018/11/22 Parkinsonism and Anesthesia

Peri-operative management Other drugs known to exacerbate extrapyramidal stimulation Dopaminergic antagonist: droperiadol Antihistamine drugs: phenothiazine Mixed dopamine blocker: metoclopramide Sympathetic blocker: reserpine 2018/11/22 Parkinsonism and Anesthesia

Post-operative management If the patient is on “off ”stage, chest stiffness, laryngospasm and facial violent tremor will result in delaying the extubation GI dysfunction is common esp. lapa and presents with dysphagia and sialorrhea. That will increase the risk of aspiration pneumonia More likely to develop confusion and hallucianation 2018/11/22 Parkinsonism and Anesthesia

Parkinsonism and Anesthesia Any Question ? 2018/11/22 Parkinsonism and Anesthesia